Newsfeeds - Spark Newswire

1 minute read

Best-Selling Drugs by Bristol Myers, Pfizer, AbbVie Likely Candidates For US Price Negotiation

Today, 6:47 AM

Bristol Myers Squibb & Co’s (NYSE:BMY) Eliquis, Pfizer Inc’s (NYSE:PFE) Ibrance, and AbbVie Inc’s (NYSE:ABBV) Imbruvica are expected to be among the ten…

ABBV

2 minute read

How Is The Market Feeling About Bristol-Myers Squibb?

By Benzinga Insights

Today, 6:47 AM

Bristol-Myers Squibb’s (NYSE:BMY) short percent of float has fallen 14.29% since its last report. The company recently reported…

BMY

1 minute read

Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason

By Vandana Singh

Today, 6:47 AM

The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…

ABBV

1 minute read

Analyst Ratings

Where Bristol-Myers Squibb Stands With Analysts

By Benzinga Insights

Today, 6:47 AM

Within the last quarter, Bristol-Myers Squibb (NYSE:BMY) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

BMY

1 minute read

Jefferies Initiates Coverage On Bristol-Myers Squibb with Hold Rating, Announces Price Target of $62

By Benzinga Newsdesk

Today, 6:47 AM

Jefferies analyst Akash Tewari initiates coverage on Bristol-Myers Squibb (NYSE:BMY) with a Hold rating and announces Price Target of $62.

BMY

1 minute read

The European Commission Has Approved Bristol Myers Squibb’s Reblozyl (Luspatercept) For Anemia Associated With Non-transfusion-dependent Beta-thalassemia

By Benzinga Newsdesk

Today, 6:47 AM

The EC approval of Reblozyl was based on results from the Phase 2 BEYOND study, evaluating the efficacy and safety of Reblozyl versus placebo in 145 adults with NTD beta thalassemia. Patients were

BMY

1 minute read

Bristol Myers’ Opdivo Shows Improved Clinical Benefits In Bladder Cancer At Three Years

By Vandana Singh

Today, 6:47 AM

Bristol-Myers Squibb Co (NYSE:BMY) announced three-year follow-up results from the Phase 3 CheckMate -274 Phase 3 trial of Opdivo compared to placebo…

BMY

4 minute read

Bristol Myers Squibb Announces Adjuvant Opdivo Continues To Provide Significant, Durable Clinical Benefits For Patients With Radically Resected, High-Risk Muscle-Invasive Urothelial Carcinoma After Three Years In CheckMate -274 Trial

By Happy Mohamed

Today, 6:47 AM

Three-year median follow-up data demonstrate significantly improved disease-free survival, non-urothelial tract recurrence-free survival, distant metastasis-free survival and second progression-free survival with

BMY

5 minute read

Opdivo In Combination With CABOMETYX Shows Durable Survival With Over Three Years Of Follow-Up In The CheckMate -9ER Trial In First-Line Advanced Renal Cell Carcinoma

By Happy Mohamed

Today, 6:47 AM

Data to be featured at ASCO GU 2023 demonstrate continued overall survival, progression-free survival and objective response rate benefits with Opdivo in combination with CABOMETYX compared to

BMY

1 minute read

Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients

By Vandana Singh

Today, 6:47 AM

Bristol-Myers Squibb & Co (NYSE:BMY) and 2seventy bio Inc (NASDAQ:TSVT) announced the first publication and presentation of results from the KarMMa-3 Phase 3 study…

BMY